“These findings highlight the potential of self-complementary AAVs to reduce dose requirements, minimize toxicity, adn broaden clinical use of inner-ear therapies,” said the head researcher.
an innovative method of gene therapy to treat hearing and balance disabilities caused by impaired function of the inner ear has been developed by researchers at Tel Aviv University (TAU). They said that this treatment, which was conducted on a mutant mouse model, offers a marked improvement over existing strategies, is more efficient, and could treat a wide range of mutations that cause hearing loss.
The study was led by Prof. Karen Avraham, dean of the Gray Faculty of Medical and Health Sciences, who is also a geneticist at the department of Human Molecular Genetics and Biochemistry at the faculty and holds the Sarah and Felix Dumont Chair for research of Hearing Disorders. she was assisted by doctoral student Roni Hahn,who worked in collaboration with Prof.Jeffrey Holt and Dr. gwenaëlle Géléoc from Boston Children’s Hospital and Harvard Medical School.
Featured on the cover of the journal EMBO Molecular Medicine and titled “AAV gene therapy rescues hearing and balance in a model of CLIC5 deafness,” it was supported by the US-Israel Binational Science Foundation (BSF),the National Institutes of Health/NIDCD,and the Israel Science Foundation Breakthrough Research Program. The team has worked with the Americans for four years, so there was no danger of losing the grant, a problem that has begun to crop up in the US and elsewhere due to cutbacks by the federal government and anti-Israel feeling in universities around the world, Avraham said.
As of 2023, the Central bureau of Statistics reported that around 60,000 younger Israelis suffer from hearing loss; the number of those who develop deafness due to aging is probably much larger.
Thus, hearing loss – the most common sensory disorder worldwide, more than blindness and other such disabilities – has long been explored as a condition amenable to gene therapy and involves over 220 different genes.In this study, the researchers investigated a mutation in the CLIC5 gene, which is vital for maintaining the stability and function of hair cells in the auditory and vestibular systems. Deficiency of this gene causes progressive deterioration of hair cells, at first leading to hearing loss and later causing balance problems.
Gene Therapy Shows Promise in Restoring hearing in Genetic Forms of Hearing loss
November 9, 2025 – Researchers are making significant strides in developing gene therapies to treat hearing loss caused by genetic factors. A new study highlights the potential of an advanced viral vector,self-complementary adeno-associated virus (scAAV),to efficiently deliver therapeutic genes to the inner ear,preventing hair cell degeneration and preserving hearing and balance in animal models. This research offers hope for individuals with congenital hearing loss, where over half of cases are linked to genetic causes.
Understanding Genetic hearing Loss and Gene Therapy
Hearing loss is a widespread condition, and genetic factors play a substantial role, particularly in congenital (present at birth) cases.These genetic defects can affect various parts of the auditory system, leading to a range of hearing impairments.https://www.nidcd.nih.gov/health/hearing-loss/genetic-hearing-loss
Gene therapy aims to correct these underlying genetic issues by introducing a functional copy of the defective gene into the patient’s cells. Viruses, specifically adeno-associated viruses (AAVs), are frequently enough used as vectors – delivery systems – for this genetic material. AAVs are favored becuase they are generally non-pathogenic and can effectively target specific cells.
The Role of scAAV in Enhanced Gene Delivery
The study, led by researchers at[InsertInstitutionName-[InsertInstitutionName-research needed to fill this in], focused on utilizing a structurally optimized version of the AAV vector: the self-complementary AAV (scAAV).Unlike traditional AAV vectors which deliver single-stranded DNA, scAAV delivers a double-stranded DNA genome directly into the cell.
“They found that this vector achieved faster and more efficient transduction of hair cells – the process by which mechanical vibrations are converted into electrical signals in the inner ear -compared to traditional AAV methods, thus it requires a lower dose to achieve a similar therapeutic effect,” according to the research.
This increased efficiency is crucial for several reasons:
* Lower Dose Requirements: Reducing the amount of viral vector needed minimizes potential toxicity and side effects.
* Faster Action: rapid gene delivery can lead to quicker therapeutic benefits.
* Broader Applicability: Improved efficiency expands the potential for treating a wider range of hearing disorders.
Promising Results in Animal Models
In preclinical studies using animal models,the scAAV-based gene therapy successfully prevented the degeneration of hair cells,which are essential for hearing. Importantly,the treatment also preserved normal hearing and balance functions. These findings suggest a strong potential for translating this approach to human clinical trials.
“These findings highlight the potential of self-complementary AAVs to reduce dose requirements, minimize toxicity, and broaden clinical use of inner-ear therapies,” stated[Quotesource-[Quotesource-research needed to fill this in].
Gene Therapy in the Wider Context of Genetic Disorders
The advancement of gene therapies for hearing loss aligns with broader advancements in the field. Gene therapy is now being applied to treat a growing number of genetic disorders, including spinal muscular atrophy (SMA) and is also being explored in cancer immunotherapy, such as CAR T-cell therapy. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy
Current Clinical Trials and Future Outlook
AAV-based gene therapy for hearing loss is already being investigated in clinical trials, with early results appearing promising. Researchers are optimistic that the findings from this study will accelerate the development of gene therapies for a wide spectrum of genetically caused hearing disorders.
“We expect that these findings will pave the way for developing gene therapies to treat a wide range of genetically caused hearing disorders,”[Quotesource-[Quotesource-research needed to fill this in].
Key Takeaways:
* Genetic factors contribute to over half of congenital hearing loss cases.
* scAAV vectors offer a more efficient method for delivering therapeutic genes to the inner ear compared to traditional AAV vectors.
* Preclinical studies demonstrate that scAAV-based gene therapy can prevent hair cell degeneration and preserve hearing and balance.
* Gene therapy for hearing loss is an active area of research with ongoing clinical trials.
FAQ:
Q: What is an AAV vector?
A: An adeno-associated virus (AAV) vector is a modified virus used to deliver genetic material into cells. AAVs are chosen for their safety profile and ability to target specific tissues.
Q: What is the difference between AAV and scAAV?
A: Traditional AAV vectors deliver single-stranded DNA, while self-complementary AAV (scAAV) delivers double